What is Embark Veterinary?
Embark Veterinary is a pioneering genetics company focused on canine DNA testing. By analyzing a dog's genetic makeup, Embark provides insights into breed composition, potential health predispositions, physical traits, and familial connections. The data gathered is instrumental in fueling new research aimed at improving the longevity and health of dogs globally. Based in Boston, Massachusetts, the company operates at the intersection of pet care, advanced diagnostics, and scientific research, leveraging its proprietary technology to advance veterinary science.
How much funding has Embark Veterinary raised?
Embark Veterinary has raised a total of $91.3M across 4 funding rounds:
Other Financing Round
$1.8M
Other Financing Round
$4.5M
Series A
$10M
Series B
$75M
Other Financing Round (2016): $1.8M with participation from AGO Partners, Slow Ventures, and Fabrice Grinda
Other Financing Round (2017): $4.5M led by SV Angel, Section 32, Anne Wojcicki, and Founder Collective
Series A (2019): $10M supported by Third Kind Venture Capital, Slow Ventures, FJ Labs, Anne Wojciciki, Freestyle Capital, F-Prime Capital Partners, and Section 32
Series B (2021): $75M featuring F-Prime Capital Partners, Third Kind Venture Capital, Slow Ventures, SoftBank Group, SV Angel, and Freestyle Capital
Key Investors in Embark Veterinary
Third Kind Venture Capital
Third Kind Venture Capital is a venture capital firm specializing in early-stage investments, with a preference for consumer internet, software, and financial services sectors.
FJ Labs
FJ Labs specializes in angel investing at a venture scale, focusing on marketplaces and network effect businesses, and has a track record of investing in successful unicorn companies.
Freestyle Capital
Freestyle VC is an early-stage venture capital firm that invests in technology companies, often taking a lead role in seed investments and providing strategic guidance to entrepreneurs.
What's next for Embark Veterinary?
The substantial enterprise-level funding indicates Embark Veterinary is poised for a significant scaling phase. This capital injection will likely be directed towards expanding its research capabilities, enhancing its technological platform, and broadening its market reach. The strategic nature of the recent investment suggests a focus on deepening its impact in veterinary diagnostics and personalized pet health, potentially leading to new product development and strategic partnerships within the animal health industry.
See full Embark Veterinary company page
